Key Highlights

  • Valion Bio shares closed down 29% at $0.37.
  • Valion Bio and Sheba Medical Center finalized an agreement to fund and execute a clinical trial of Entolimod.
  • The study will involve up to 10 irradiated oncology patients.
  • The trial evaluates Entolimod for radiation-induced neutropenia.

Valion Bio (NASDAQ: VBIO) shares closed down 29% at $0.37 even after the company and Sheba Medical Center finalized an agreement to fund and execute a clinical trial of Entolimod.

What Happened

The study, which will involve up to 10 irradiated oncology patients, is designed to evaluate Entolimod as a treatment for radiation-induced neutropenia.

The partnership establishes what the company describes as a capital-efficient expansion of Valion's oncology-supportive pipeline, complementing its primary medical countermeasure program for Acute Radiation Syndrome.

Market Reaction

Shares fell 29% to close at $0.37 despite the new trial agreement, a decline that stands in contrast to the positive framing of the Sheba partnership in the company's disclosure.

The disclosed information does not specify a reason for the share price decline beyond the trial announcement itself.

Outlook

The trial's small scale, up to 10 irradiated oncology patients, positions it as an early, capital-efficient step in Valion's oncology-supportive pipeline, according to the disclosed information.

What did Valion Bio and Sheba Medical Center agree to?

They finalized an agreement to fund and execute a clinical trial of Entolimod involving up to 10 irradiated oncology patients.

What is Entolimod being tested for in this trial?

The trial evaluates Entolimod as a treatment for radiation-induced neutropenia.

Why did Valion Bio shares fall 29% despite the new trial deal?

The disclosed information does not specify a reason for the decline beyond the announcement itself.